Core Viewpoint - Bone Biologics Corporation is advancing its product candidate NB1 into human clinical testing for spinal fusion, with three hospital sites engaged for a pilot clinical trial evaluating its safety and effectiveness in treating degenerative disc disease [1][2]. Company Overview - Bone Biologics Corporation focuses on regenerative medicine for bone, particularly through its NB1 bone graft device, which is designed for spinal fusion procedures and has potential applications in trauma and osteoporosis [5]. Product Details - NB1 is a recombinant human protein (rhNELL-1) combined with demineralized bone matrix, aimed at enhancing bone regeneration and healing, especially in challenging cases [3]. - The mechanism of action for rhNELL-1 involves receptor binding and intracellular signaling to promote osteogenic gene expression and bone formation [3]. Market Opportunity - The global market for bone graft substitutes in spine fusion is estimated at $3 billion annually, with additional long-term opportunities in the $11 billion market for osteoporosis treatment and the $8 billion market for trauma treatment [4].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, $0.001 par value per share BBLG The Nasdaq Capital Market Warrants to Purchase Common stock, $0.001 par value per share BBLGW The Nasdaq Capital Market Emerging growth company ☐ FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 ☐ TRANSITION REPORT PURSUA ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Delaware 42-1743430 (State or other jurisdiction of incorporation or formation) (I.R.S. employer identification number) Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, $0.001 par value per share BBLG The Nasdaq Capital Market Warrants to Purchase Common stock, $0.001 par value per share BBLGW The Nasdaq Capital Market Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smal ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Delaware 42-1743430 (State or other jurisdiction of incorporation or formation) (I.R.S. employer identification number) Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, $0.001 par value per share BBLG The Nasdaq Capital Market Warrants to Purchase Common stock, $0.001 par value per share BBLGW The Nasdaq Capital Market Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smal ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Delaware 42-1743430 (State or other jurisdiction of incorporation or formation) (I.R.S. employer identification number) Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, $0.001 par value per share BBLG The Nasdaq Stock Market LLC Warrants to Purchase Common stock, $0.001 par value per share BBLGW The Nasdaq Stock Market LLC Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, $0.001 par value per share BBLG The Nasdaq Stock Market LLC Warrants to Purchase Common stock, $0.001 par value per share BBLGW The Nasdaq Stock Market LLC FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Fo ...